Biosimilars for psoriasis: clinical studies to determine similarity

British Journal of Dermatology

Volumn 177, Issue 1, 2017, Pages 23-33

  Blauvelt, A ^a   Puig, L ^b   Chimenti, S ^c   Vender, R ^d,e   Rajagopalan, M ^f   Romiti, R ^g   Skov, L ^h   Zachariae, C ^h   Young, H ⁱ   Prens, E ^j   Cohen, A ^k,l   van der Walt, J ^m   Wu, J J ⁿ  

^a OREGON MEDICAL RESEARCH CENTER   (United States)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d Dermatrials Research   (Canada)

^e Dermatrials Research Inc Venderm Innovations in Psoriasis   (Canada)

^f APOLLO HOSPITALS   (India)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h UNIVERSITY OF COPENHAGEN   (Denmark)

ⁱ UNIVERSITY OF MANCHESTER   (United Kingdom)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^l CLALIT HEALTH SERVICES   (Israel)

^m International Psoriasis Council   (United States)

ⁿ KAISER PERMANENTE MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; MONOCLONAL ANTIBODY;

EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CLINICAL TRIAL (TOPIC); DRUG APPROVAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; BIOSIMILAR PHARMACEUTICALS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; PRACTICE GUIDELINES AS TOPIC; PSORIASIS;

EID: 85019723172     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.15067     Document Type: Review

References (57)

1. Weise M, Bielsky MC, De Smet K et al. Biosimilars – why terminology matters. Nat Biotechnol 2011; 29:690–3.
2. Kálmán-Szekeres Z, Olajos M, Ganzler K. Analytical aspects of biosimilarity issues of protein drugs. J Pharm Biomed Anal 2012; 69:185–95.
3. Staidle JP, Dabade TS, Feldman SR. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother 2011; 12:2041–54.
4. Horn EJ, Fox KM, Patel V et al. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol 2007; 57:957–62.
5. Calvo B, Zuñiga L. The US approach to biosimilars: the long-awaited FDA approval pathway. BioDrugs 2012; 26:357–61.
6. European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf (last accessed 9 April 2017).
7. Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J 2014; 16:22–6.
8. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Biosimilars: additional questions and answers regarding implementation of the biologics price competition and innovation act of 2009. Guidance for industry. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM273001.pdf (last accessed 9 April 2017).
9. Ebbers HC. Biosimilars: in support of extrapolation of indications. J Crohns Colitis 2014; 8:431–5.
10. Strober BE, Armour K, Romiti R et al. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. J Am Acad Dermatol 2012; 66:317–22.
11. Scott BJ, Klein AV, Wang J. Biosimilar monoclonal antibodies: a Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation. J Clin Pharmacol 2015; 55 (Suppl. 3):S123–32.
12. ® (biosimilar infliximab) for three additional indications: Crohn's disease, fistulising Crohn's diease and ulcerative colitits. Available at: http://www.pfizer.ca/node/7526 (last accessed 24 April 2017).
13. Tsiftsoglou AS, Trouvin JH, Calvo G et al. Demonstration of biosimilarity, extrapolation of indications and other challenges related to biosimilars in Europe. BioDrugs 2014; 28:479–86.
14. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349:2014–22.
15. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366:1367–74.
16. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000; 343:1594–602.
17. Regan BP, Bousvaros A. Pediatric ulcerative colitis: a practical guide to management. Paediatr Drugs 2014; 16:189–98.
18. Tóthfalusi L, Endrényi L, Chow SC. Statistical and regulatory considerations in assessments of interchangeability of biological drug products. Eur J Health Econ 2014; 15 (Suppl. 1):S5–11.
19. Sarpatwari A, Avorn J, Kesselheim AS. Progress and hurdles for follow-on biologics. N Engl J Med 2015; 372:2380–2.
20. European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf (last accessed 9 April 2017).
21. European Commission. Consensus Information Paper 2013. What you need to know about Biosimilar Medicinal Products. Available at: http://ec.europa.eu/DocsRoom/documents/8242/attachments/1/translations/en/renditions/native (last accessed 9 April 2017).
22. Lucio SD, Stevenson JG, Hoffman JM. Biosimilars: Implications for health-system pharmacists. Am J Health Syst Pharm 2013; 70:2004–17.
23. Kurki P, Ekman N. Biosimilar regulation in the EU. Expert Rev Clin Pharmacol 2015; 8:649–59.
24. Tóthfalusi L, Endrényi L, Chow SC. Statistical and regulatory considerations in assessments of interchangeability of biological drug products. Eur J Health Econ 2014; 15 (Suppl. 1):S5–11.
25. Sood R, Morisot S, Kokolus R. Five strategic considerations for biosimilar commercialization. Available at: http://obroncology.com/article/five-strategic-considerations-for-biosimilar-commercialization-2/ (last accessed 9 April 2017).
26. Yoo DH. Efficacy and safety of CT-P13 (Infliximab biosimilar) over two years in patients with rheumatoid arthritis: 20. Comparison between continued CT-P13 and switching from Infliximab to CT-P13. ACR Annual Meeting, San Diego, CA, U.S.A., 25–30 October 2013; abstr. L1.
27. Yoo DH, Prodanovic N, Jaworski J et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis 2017; 76:355–63.
28. Park W, Yoo DH, Miranda P et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis 2017; 76:346–54.
29. Fiorino G. Prospective observational study on inflammatory bowel disease patients treated with infliximab biosimilars: preliminary results of the PROSIT-BIO cohort of the IG-IBD. Presented at the 11th Congress of the European Crohn's and Colitis Organisation, Amsterdam, the Netherlands, 16–19 March 2016.
30. Diaz Hernandez L. Efficacy and safety of switching between originator and biosimilar infliximab in patients with inflammatory bowel disease in practical clinic: results to 6 months. Presented at the 11th Congress of the European Crohn's and Colitis Organisation, Amsterdam, the Netherlands, 16–19 March 2016.
31. ®) to biosimilar infliximab (Remsima™) is effective and safe. Presented at the 11th Congress of the European Crohn's and Colitis Organisation, Amsterdam, the Netherlands, 16–19 March 2016.
32. Jørgensen KK, Olsen IC, Goll GL, on behalf of the show NOR-SWITCH study group et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017; https://doi.org/10.1016/S0140-6736(17)30068-5
33. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM397017.pdf (last accessed 9 April 2017).
34. Anderson S, Hauck WW. Consideration of individual bioequivalence. J Pharmacokinet Biopharm 1990; 18:259–73.
35. Ebbers HC, Muenzberg M, Schellekens H. The safety of switching between therapeutic proteins. Expert Opin Biol Ther 2012; 12:1473–85.
36. Ebbers HC, Crow SA, Vulto AG et al. Interchangeability, immunogenicity and biosimilars. Nat Biotechnol 2012; 30:1186–90.
37. Casadevall N, Thorpe R, Schellekens H. Biosimilars need comparative clinical data. Kidney Int 2011; 80:553.
38. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Scientific considerations in demonstrating biosimilarity to a reference product 2012. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf (last accessed 9 April 2017).
39. Kozlowski S. Biosimilars – an update focused on quality considerations. Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugsadvisorycommitteeforpharmaceuticalscienceandclinicalpharmacology/ucm315764.pdf (last accessed 9 April 2017).
40. Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58:106–15.
41. Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med 2014; 371:326–38.
42. Griffiths CE, Reich K, Lebwohl M et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386:541–51.
43. Lebwohl M, Strober B, Menter A et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015; 373:1318–28.
44. Kopp T, Riedl E, Bangert C et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature 2015; 14:222–6.
45. Gordon KB, Duffin KC, Bissonnette R et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med 2015; 373:136–44.
46. Krueger JG, Ferris LK, Menter A et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2015; 136(116–24):e7.
47. Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis 2013; 72:315–18.
48. Generics and Biosimilars Initiative. FDA accepts application for etanercept biosimilar. Available at: http://www.gabionline.net/layout/set/print/Biosimilars/News/FDA-accepts-application-for-etanercept-biosimilar (last accessed 9 April 2017).
49. Generics and Biosimilars Initiative. Biosimilars approved in South Korea. Available at: http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-South-Korea (last accessed 9 April 2017).
50. PR Newswire. Intas Pharmaceuticals launches INTACEPT, the first etanercept biosimilar. Available at: http://gabionline.net/Biosimilars/News/TNF-copy-biological-approved-in-China (last accessed 9 April 2017).
51. Generics and Biosimilars Initiative. TNF copy biological approved in China. Available at: http://www.prnewswire.co.in/news-releases/intas-pharmaceuticals-launches-intacept-the-first-etanercept-biosimilar-497747161.html (last accessed 9 April 2017).
52. Jani RH, Gupta R, Bhatia G et al. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. Int J Rheum Dis 2016; 19:1157–68.
53. Dörner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol 2015; 11:713–24.
54. Generics and Biosimilars Initiative. Infliximab ‘similar biologic’ receives Indian approval. Available at: http://www.gabionline.net/layout/set/print/Biosimilars/News/Infliximab-similar-biologic-receives-Indian-approval (last accessed 9 April 2017).
55. Health Canada. Guidance document: information and submission requirements for biosimilar biologic drugs. Available at: http://www.hc-sc.gc.ca/dhp-mps/brgtherap/applic-demande/guides/biosimilars-biosimilaires-eng.php (last accessed 10 April 2017).
56. European Medicines Agency. Remsima. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002576/human_med_001682.jsp&mid=WC0b01ac058001d124 (last accessed 9 April 2017).
57. European Medicines Agency. Assessment report. Remsima. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf (last accessed 9 April 2017).